HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

HUTCHMED (China) LimitedNASDAQ: HCM

Weighted Avg Shares · Q2 FY2025 · quarter ended Jun 2025

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2025 weighted avg shares of 174.98M shares rose 1.7% year over year, behind the +20.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.7% toward the trailing-twelve-month pace of +20.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
174.98M+0.0% QoQ
Last fiscal yearDec 2025
171.66M+0.3% YoY
LTMJun 2025
206.7M+20.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.7%——
1 year+0.3%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
171.66M USD
Year-over-year change
+0.3%
4-year CAGR
+2.0%

Weighted Avg Shares vs competitors

How HCM compares with its peers on the latest reported figures

  • HCM's LTM Jun 2025 weighted avg shares of 206.7M shares is the 4th highest of the 11 companies compared; the peer median is 151.11M shares.
  • Its year-over-year change of +20.7% is the 2nd highest of 9, against a peer median of +3.8%.
  • Over three fiscal years its annual growth of +0.4% compares with a peer median of +6.5%.
HCM Competitors Peer median
Weighted Avg Shares for HCM and competitors
Company Period LTM YoY 3-year CAGR
GMABGenmab A/SLTM Jun 2026614.84M —-1.7%
EXELExelixis, Inc.LTM Jul 2026262.28M -6.5%-5.5%
BNTXBioNTech SELTM Jun 2026247.64M +3.0%-0.2%
HCMHUTCHMED (China) LimitedLTM Jun 2025206.7M +20.7%+0.4%
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +20.1%+14.3%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.85M +4.6%+28.8%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
Peer median (excluding HCM) 151.11M+3.8%+6.5%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.